These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 24819296)

  • 1. A soluble form of CD80 enhances antitumor immunity by neutralizing programmed death ligand-1 and simultaneously providing costimulation.
    Haile ST; Horn LA; Ostrand-Rosenberg S
    Cancer Immunol Res; 2014 Jul; 2(7):610-5. PubMed ID: 24819296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes.
    Horn LA; Long TM; Atkinson R; Clements V; Ostrand-Rosenberg S
    Cancer Immunol Res; 2018 Jan; 6(1):59-68. PubMed ID: 29122838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression.
    Haile ST; Dalal SP; Clements V; Tamada K; Ostrand-Rosenberg S
    J Immunol; 2013 Sep; 191(5):2829-36. PubMed ID: 23918985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
    Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
    J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting CD28, CTLA-4 and PD-L1 costimulation differentially controls immune synapses and function of human regulatory and conventional T-cells.
    Dilek N; Poirier N; Hulin P; Coulon F; Mary C; Ville S; Vie H; Clémenceau B; Blancho G; Vanhove B
    PLoS One; 2013; 8(12):e83139. PubMed ID: 24376655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells.
    Ostrand-Rosenberg S; Horn LA; Alvarez JA
    Cancer Immunol Immunother; 2015 Oct; 64(10):1287-93. PubMed ID: 25792524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells.
    Ni X; Song Q; Cassady K; Deng R; Jin H; Zhang M; Dong H; Forman S; Martin PJ; Chen YZ; Wang J; Zeng D
    J Clin Invest; 2017 May; 127(5):1960-1977. PubMed ID: 28414296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes.
    Keir ME; Latchman YE; Freeman GJ; Sharpe AH
    J Immunol; 2005 Dec; 175(11):7372-9. PubMed ID: 16301644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity.
    Ostrand-Rosenberg S; Horn LA; Haile ST
    J Immunol; 2014 Oct; 193(8):3835-41. PubMed ID: 25281753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells.
    Tekguc M; Wing JB; Osaki M; Long J; Sakaguchi S
    Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costimulation of IL-2 Production through CD28 Is Dependent on the Size of Its Ligand.
    Lim HS; Cordoba SP; Dushek O; Goyette J; Taylor A; Rudd CE; van der Merwe PA
    J Immunol; 2015 Dec; 195(11):5432-9. PubMed ID: 26500347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1.
    Kleinpeter P; Remy-Ziller C; Winter E; Gantzer M; Nourtier V; Kempf J; Hortelano J; Schmitt D; Schultz H; Geist M; Brua C; Hoffmann C; Schlesinger Y; Villeval D; Thioudellet C; Erbs P; Foloppe J; Silvestre N; Fend L; Quemeneur E; Marchand JB
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30918073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple layers of CD80/86-dependent costimulatory activity regulate primary, memory, and secondary lymphocytic choriomeningitis virus-specific T cell immunity.
    Eberlein J; Davenport B; Nguyen TT; Victorino F; Sparwasser T; Homann D
    J Virol; 2012 Feb; 86(4):1955-70. PubMed ID: 22156513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New expression of PD-L1 on activated CD4
    Mazerolles F
    Hum Immunol; 2024 Jul; 85(4):110831. PubMed ID: 38870593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A potential new pathway for PD-L1 costimulation of the CD8-T cell response to Listeria monocytogenes infection.
    Xu D; Fu HH; Obar JJ; Park JJ; Tamada K; Yagita H; Lefrançois L
    PLoS One; 2013; 8(2):e56539. PubMed ID: 23409193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD80 Expressed by CD8
    Rollins MR; Gibbons Johnson RM
    J Immunol Res; 2017; 2017():7659462. PubMed ID: 29181416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemagglutinating virus of Japan-envelope containing programmed cell death-ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma.
    Sugii N; Matsuda M; Okumura G; Shibuya A; Ishikawa E; Kaneda Y; Matsumura A
    Cancer Sci; 2021 Jan; 112(1):81-90. PubMed ID: 33155337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Restriction of PD-1 function by
    Sugiura D; Maruhashi T; Okazaki IM; Shimizu K; Maeda TK; Takemoto T; Okazaki T
    Science; 2019 May; 364(6440):558-566. PubMed ID: 31000591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity.
    Zhang Y; Song Q; Cassady K; Lee M; Tang H; Zheng M; Wang B; Schones DE; Fu YX; Riggs AD; Martin PJ; Feng R; Zeng D
    Proc Natl Acad Sci U S A; 2023 Apr; 120(16):e2205085120. PubMed ID: 37036990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic Cell-Targeted Nanoparticles Enhance T Cell Activation and Antitumor Immune Responses by Boosting Antigen Presentation and Blocking PD-L1 Pathways.
    Srivastava P; Rütter M; Antoniraj G; Ventura Y; David A
    ACS Appl Mater Interfaces; 2024 Oct; 16(40):53577-53590. PubMed ID: 39344665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.